ENDRA Life Sciences (NDRA) Cash & Equivalents (2016 - 2026)

ENDRA Life Sciences has disclosed Cash & Equivalents across 11 years of filings, most recently posting $356462.0 for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 82.74% year-over-year to $356462.0; the TTM figure through Mar 2026 stood at $356462.0 (down 82.74% YoY), while the FY2025 annual figure was $762365.0, down 76.39% from the prior year.
• Cash & Equivalents declined to $356462.0 in Q1 2026, from $762365.0 in the prior quarter.
• Over the last five years, Cash & Equivalents for NDRA reached as high as $11.3 million in Q2 2022 and fell as low as $356462.0 in Q1 2026.
• The 5-year median for Cash & Equivalents is $3.2 million (2024), against an average of $3.9 million.
• The widest YoY moves for Cash & Equivalents: up 81.98% in 2025, down 83.27% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $4.9 million in 2022, then tumbled by 42.04% to $2.8 million in 2023, then grew by 13.96% to $3.2 million in 2024, then plunged by 76.39% to $762365.0 in 2025, then tumbled by 53.24% to $356462.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $356462.0, $762365.0, and $794036.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.